Investor Centre

• IND approved to trial PXS-5505 added to current standard of care in newly diagnosed unresectable hepatocellular carcinoma patients
• University of Rochester Medical Center and Pharmaxis in discussions to commence investigator-led study in 2022

Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 28 October 2021.

Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 1.00pm AET on Thursday 28 October 2021.

The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.

To register and receive your conference link please click here.

Upon registration, instructions for joining the session will be sent via email.

To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: david.mcgarvey@pharmaxis.com.au

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that it has commenced dosing in the phase 2 clinical trial studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis.